Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses.
Dobrzanski MJ, Reome JB, Hollenbaugh JA, Dutton RW. Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses. J Immunol. 2004 Feb 01; 172(3):1380-90.
-
Animals
-
CD4-Positive T-Lymphocytes
-
CD8-Positive T-Lymphocytes
-
Cell Line, Tumor
-
Cells, Cultured
-
Chemokines
-
Cytokines
-
Cytotoxicity, Immunologic
-
Epitopes, T-Lymphocyte
-
Female
-
Immunity, Cellular
-
Immunophenotyping
-
Immunotherapy, Adoptive
-
Interferon-gamma
-
Lung
-
Lung Neoplasms
-
Lymphocyte Activation
-
Melanoma, Experimental
-
Membrane Glycoproteins
-
Mice
-
Mice, Inbred C57BL
-
Mice, Knockout
-
Mice, Transgenic
-
Neoplasm Transplantation
-
Ovalbumin
-
Perforin
-
Pore Forming Cytotoxic Proteins
-
Survival Analysis
-
T-Lymphocytes, Regulatory
-
Tumor Necrosis Factor-alpha
-
Up-Regulation